These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 23401459)

  • 1. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.
    Villa D; Crump M; Panzarella T; Savage KJ; Toze CL; Stewart DA; MacDonald DA; Buckstein R; Lee C; Alzahrani M; Rubinger M; Foley R; Xenocostas A; Sabloff M; Muccilli A; Chua N; Couture F; Larouche JF; Cohen S; Connors JM; Ambler K; Al-Tourah A; Ramadan KM; Kuruvilla J
    J Clin Oncol; 2013 Mar; 31(9):1164-71. PubMed ID: 23401459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
    Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
    Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.
    Pettengell R; Schmitz N; Gisselbrecht C; Smith G; Patton WN; Metzner B; Caballero D; Tilly H; Walewski JA; Bence-Bruckler I; To B; Geisler CH; Schots R; Kimby E; Taverna CJ; Kozák T; Dreger P; Uddin R; Ruiz de Elvira C; Goldstone AH
    J Clin Oncol; 2013 May; 31(13):1624-30. PubMed ID: 23547078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma.
    Villa D; George A; Seymour JF; Toze CL; Crump M; Lee C; Buckstein R; Stewart DA; MacDonald D; Foley R; Xenocostas A; Sabloff M; Chua N; Couture F; Larouche JF; Cohen S; Savage KJ; Connors JM; Panzarella T; Carney DA; Dickinson M; Kuruvilla J
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1813-8. PubMed ID: 25042735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.
    Ban-Hoefen M; Vanderplas A; Crosby-Thompson AL; Abel GA; Czuczman MS; Gordon LI; Kaminski MS; Kelly J; Millenson M; Nademanee AP; Rodriguez MA; Zelenetz AD; Niland J; LaCasce AS; Friedberg JW
    Br J Haematol; 2013 Nov; 163(4):487-95. PubMed ID: 24111533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.
    Chen YB; Li S; Fisher DC; Driscoll J; Del Rio C; Abramson J; Armand P; Barnes J; Brown J; Cutler C; El-Jawahri A; Ho VT; Hochberg E; McAfee S; Takvorian R; Spitzer TR; Antin JH; Soiffer R; Jacobsen E
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1583-8. PubMed ID: 26009261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis.
    Limvorapitak W; Barnett MJ; Hogge DE; Forrest DL; Nevill TJ; Narayanan S; Power MM; Nantel SH; Broady R; Song KW; Toze CL; Mourad YA; Sutherland HJ; Gerrie AS; White J; Sanford DS
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e481-e491. PubMed ID: 30100330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-remission treatment for adult patients with acute lymphoblastic leukemia in first remission: is there a role for autologous stem cell transplantation?
    Willemze R; Labar B
    Semin Hematol; 2007 Oct; 44(4):267-73. PubMed ID: 17961726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant.
    Khouri IF; Milton DR; Gulbis AM; Jabbour EJ; Nastoupil L; Ledesma C; Anderlini P; Bashir Q; Daher M; Im JS; Iyer SP; Marin D; Mehta RS; Olson AL; Popat UR; Qazilbash M; Saini N; Samaniego F; Rondon G; Medeiros LJ; Champlin RE
    Clin Cancer Res; 2021 Nov; 27(21):5847-5856. PubMed ID: 34380640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.
    Sebban C; Brice P; Delarue R; Haioun C; Souleau B; Mounier N; Brousse N; Feugier P; Tilly H; Solal-Céligny P; Coiffier B
    J Clin Oncol; 2008 Jul; 26(21):3614-20. PubMed ID: 18559872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).
    Dietrich S; Boumendil A; Finel H; Avivi I; Volin L; Cornelissen J; Jarosinska RJ; Schmid C; Finke J; Stevens WB; Schouten HC; Kaufmann M; Sebban C; Trneny M; Kobbe G; Fornecker LM; Schetelig J; Kanfer E; Heinicke T; Pfreundschuh M; Diez-Martin JL; Bordessoule D; Robinson S; Dreger P
    Ann Oncol; 2014 May; 25(5):1053-8. PubMed ID: 24585719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective phase II study of RICE re-induction, then high-dose fludarabine and busulfan, followed by autologous or allogeneic blood stem cell transplantation for indolent b-cell lymphoma.
    Stewart DA; Duan Q; Carlson L; Russell JA; Bahlis NJ; Duggan P; Hasegawa W; Voralia M
    Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):475-82. PubMed ID: 21831743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin.
    Stein RS; Greer JP; Goodman S; Kallianpur A; Ahmed MS; Wolff SN
    Bone Marrow Transplant; 1999 Feb; 23(3):227-33. PubMed ID: 10084253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
    Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
    Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab.
    Berinstein NL; Bhella S; Pennell NM; Cheung MC; Imrie KR; Spaner DE; Milliken V; Zhang L; Hewitt K; Boudreau A; Reis MD; Chesney A; Good D; Ghorab Z; Hicks LK; Piliotis E; Buckstein R
    Ann Hematol; 2015 May; 94(5):813-23. PubMed ID: 25567231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
    Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
    Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party.
    Robinson SP; Boumendil A; Finel H; Blaise D; Poiré X; Nicolas-Virelizier E; Or R; Malladi R; Corby A; Fornecker L; Caballero D; Pohlreich D; Nagler A; Thieblemont C; Finke J; Bachy E; Vincent L; Schroyens W; Schouten H; Dreger P
    Bone Marrow Transplant; 2016 Mar; 51(3):365-71. PubMed ID: 26618550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
    Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transformed follicular lymphoma (tFL): consolidation therapy may improve survival.
    Elhassadi E; Flavin R; Browne P; Conneally E; Hayden P; Quinn F; Higgins E; Vandenberghe E
    Ir J Med Sci; 2017 Aug; 186(3):589-595. PubMed ID: 28321641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.